
News|Articles|April 1, 2003
Xalatan (latanoprost ophthalmic solution)
FDA approval of this prescription eye drop makes it the first and only prostaglandin with a first-line indication for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. Initially, latanoprost was only approved for second-line use.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026
2
Pivotal trial is recruiting for monthly GLP-1 for weight loss | ADA 2026
3
CONNECT data support CGM use in non-insulin type 2 diabetes management | ADA 2026
4
‘Fierce compassion’ could be key to minimizing shame in HIV patients
5






























